Bioneer Corporation (064550.KQ)
KRW 19520.0
(-3.84%)
KRW 19520.0
(-3.84%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 10.04 Billion KRW | -83.76% |
| 2022 | 21.78 Billion KRW | -64.05% |
| 2021 | 48.78 Billion KRW | -54.21% |
| 2020 | 62.17 Billion KRW | 1975.35% |
| 2019 | -1.11 Billion KRW | 27.93% |
| 2018 | -5.72 Billion KRW | -257.34% |
| 2017 | -4.79 Billion KRW | 70.35% |
| 2016 | -9.21 Billion KRW | -1728.14% |
| 2015 | 281.61 Million KRW | 92.16% |
| 2014 | -7.44 Billion KRW | -1006.78% |
| 2013 | -368.05 Million KRW | 746.25% |
| 2012 | -1.84 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -595 Million KRW | -109.44% |
| 2024 Q3 | -7.65 Billion KRW | -1186.89% |
| 2024 Q1 | 2.77 Billion KRW | 181.06% |
| 2023 Q4 | -7.31 Billion KRW | -271.01% |
| 2023 Q1 | 1.36 Billion KRW | 174.82% |
| 2023 Q3 | 4.27 Billion KRW | -6.9% |
| 2023 FY | - KRW | -83.76% |
| 2023 Q2 | 4.59 Billion KRW | 235.97% |
| 2022 Q3 | 5.12 Billion KRW | 397.97% |
| 2022 Q2 | 1.02 Billion KRW | -90.99% |
| 2022 FY | - KRW | -64.05% |
| 2022 Q1 | 11.41 Billion KRW | 62.66% |
| 2022 Q4 | -1.82 Billion KRW | -135.67% |
| 2021 Q3 | 863.72 Million KRW | -96.23% |
| 2021 Q2 | 22.93 Billion KRW | 22.42% |
| 2021 Q4 | 7.01 Billion KRW | 712.56% |
| 2021 FY | - KRW | -54.21% |
| 2021 Q1 | 18.73 Billion KRW | -42.63% |
| 2020 Q2 | 33.37 Billion KRW | 3686.41% |
| 2020 Q3 | 43.68 Billion KRW | 30.87% |
| 2020 Q4 | 32.65 Billion KRW | -25.23% |
| 2020 Q1 | 881.47 Million KRW | 145.53% |
| 2020 FY | - KRW | 1975.35% |
| 2019 Q1 | -1.61 Billion KRW | -139.97% |
| 2019 FY | - KRW | 27.93% |
| 2019 Q4 | -1.93 Billion KRW | -579.33% |
| 2019 Q2 | 585.31 Million KRW | 136.27% |
| 2019 Q3 | -284.99 Million KRW | -148.69% |
| 2018 Q4 | -672.47 Million KRW | 66.95% |
| 2018 Q2 | -1.69 Billion KRW | 24.62% |
| 2018 Q1 | -2.24 Billion KRW | -7.46% |
| 2018 FY | - KRW | -257.34% |
| 2018 Q3 | -2.03 Billion KRW | -20.27% |
| 2017 Q1 | 233 Million KRW | 109.81% |
| 2017 FY | - KRW | 70.35% |
| 2017 Q4 | -2.08 Billion KRW | -4857.8% |
| 2017 Q2 | -355.19 Million KRW | -252.44% |
| 2017 Q3 | -42.13 Million KRW | 88.14% |
| 2016 FY | - KRW | -1728.14% |
| 2016 Q1 | -1.4 Billion KRW | -4551.24% |
| 2016 Q2 | -1.95 Billion KRW | -39.65% |
| 2016 Q4 | -2.37 Billion KRW | 31.87% |
| 2016 Q3 | -3.48 Billion KRW | -78.18% |
| 2015 Q4 | 31.47 Million KRW | -95.66% |
| 2015 Q2 | 79.01 Million KRW | 106.3% |
| 2015 Q1 | -1.25 Billion KRW | 6.64% |
| 2015 FY | - KRW | 92.16% |
| 2015 Q3 | 725.74 Million KRW | 818.48% |
| 2014 Q3 | -1.57 Billion KRW | 7.13% |
| 2014 Q1 | -503.48 Million KRW | 24.83% |
| 2014 FY | - KRW | -1006.78% |
| 2014 Q4 | -1.34 Billion KRW | 14.91% |
| 2014 Q2 | -1.69 Billion KRW | -237.62% |
| 2013 Q2 | 245.86 Million KRW | -76.09% |
| 2013 Q4 | -669.77 Million KRW | -3883.67% |
| 2013 Q3 | -16.81 Million KRW | -106.84% |
| 2013 Q1 | 1.02 Billion KRW | -8.45% |
| 2013 FY | - KRW | 746.25% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | 1.12 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 105.83% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | 261.087% |
| BINEX Co., Ltd. | 10.87 Billion KRW | 7.624% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | 2393.89% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | 151.791% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 123.467% |
| Helixmith Co., Ltd | -53 Billion KRW | 118.948% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 85.671% |
| Medy-Tox Inc. | 32.69 Billion KRW | 69.285% |
| Peptron, Inc. | -12.65 Billion KRW | 179.39% |
| Amicogen, Inc. | 13.95 Billion KRW | 28.022% |
| Genexine, Inc. | -40.87 Billion KRW | 124.569% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | -22.038% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 114.069% |
| ALTEOGEN Inc. | 440.04 Million KRW | -2182.331% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 90.367% |
| SillaJen, Inc. | -17.35 Billion KRW | 157.878% |
| JETEMA, Co., Ltd. | 11 Billion KRW | 8.762% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | 190.194% |
| Genomictree Inc. | -6.33 Billion KRW | 258.615% |
| MedPacto, Inc. | -32.6 Billion KRW | 130.799% |
| D&D Pharmatech | -9.05 Billion KRW | 210.878% |
| EASY BIO,Inc. | 24.32 Billion KRW | 58.709% |
| GI Innovation, Inc. | -51.33 Billion KRW | 119.566% |